Nuvalent, Inc.
NUVL
Hisse Senetlerindeki Sıralama
#2111
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Hisse Fiyatı
$123.96
Son senkronizasyon: 2026-07-21
Piyasa Değeri
$9.75B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
26.53%
Ülke
US
Ticaret Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Nuvalent, Inc. (NUVL) için kazanç
Mar 2026 itibarıyla kazanç TTM: $-449.48M
Nuvalent, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-449.48M'dir. 2023 yılında şirket $-126.22M kazanç elde etti, bu 2022 yılındaki $-81.85M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Nuvalent, Inc. için kazanç geçmişi 2019 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-449.48M | 72.88% |
| 2024 | $-259.99M | 105.98% |
| 2023 | $-126.22M | 54.20% |
| 2022 | $-81.85M | 76.65% |
| 2021 | $-46.34M | 218.34% |
| 2020 | $-14.56M | 23.26% |
| 2019 | $-11.81M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,273.56% |
US
|
|
| $-3.09B | 586.80% |
US
|
|
| $-4.02B | 793.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -533.98% |
NL
|
